RVL Pharmaceuticals PLC
NASDAQ:RVLP
RVL Pharmaceuticals PLC
NASDAQ:RVLP
Price:
0.0024 USD
14.29%
Updated:
May 7, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of RVLP.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RVLP
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
RVLP Competitors Multiples
RVL Pharmaceuticals PLC Competitors
RVL Pharmaceuticals PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
RVL Pharmaceuticals PLC
NASDAQ:RVLP
|
238.5k USD | 0 | -0 | 0.4 | 0.4 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
733.8B USD | 20.4 | 119.5 | 58.5 | 66.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 16.9 | 46.8 | 34.2 | 37.3 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
358.4B USD | 4.2 | 9.3 | 11.5 | 15 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
326B USD | 5.3 | 141.4 | 35.2 | 57.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.8B GBP | 5 | 37.3 | 174.3 | 278.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
183.4B CHF | 4.3 | 13.6 | 10 | 16.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
176.5B CHF | 3 | 15.4 | 8.7 | 10.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.6B USD | 2.9 | -513.2 | 12.7 | 20.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
